Qvt Associates Gp Llc - Net Worth and Insider Trading
Qvt Associates Gp Llc Net Worth
The estimated net worth of Qvt Associates Gp Llc is at least $1.5 Billion dollars as of 2024-04-19. Qvt Associates Gp Llc is the 10% Owner of Medivation Inc and owns about 13,326,916 shares of Medivation Inc (MDVN) stock worth over $1.1 Billion. Qvt Associates Gp Llc is the 10% Owner of Urovant Sciences Ltd and owns about 22,860,013 shares of Urovant Sciences Ltd (UROV) stock worth over $371 Million. Qvt Associates Gp Llc is also the 10% Owner of Achillion Pharmaceuticals Inc and owns about 8,868,753 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $60 Million. Besides these, Qvt Associates Gp Llc also holds Sio Gene Therapies Inc (SIOX) , Agenus Inc (AGEN) . Details can be seen in Qvt Associates Gp Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Qvt Associates Gp Llc has not made any transactions after 2019-06-19 and currently still holds the listed stock(s).
Transaction Summary of Qvt Associates Gp Llc
Qvt Associates Gp Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Qvt Associates Gp Llc owns 9 companies in total, including Arbutus Biopharma Corp (ABUS) , Sio Gene Therapies Inc (SIOX) , and Myovant Sciences Ltd (MYOV) among others .
Click here to see the complete history of Qvt Associates Gp Llc’s form 4 insider trades.
Insider Ownership Summary of Qvt Associates Gp Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | 2016-07-08 | director & 10 percent owner & other: See Remarks |
| SIOX | Sio Gene Therapies Inc | 2019-03-18 | 10 percent owner |
| MYOV | Myovant Sciences Ltd | 2016-10-26 | director & 10 percent owner & other: See remarks |
| UROV | Urovant Sciences Ltd | 2019-07-10 | 10 percent owner |
| AGEN | Agenus Inc | 2014-02-05 | 10 percent owner |
| ACHN | Achillion Pharmaceuticals Inc | 2014-06-16 | 10 percent owner |
| CNCE | Concert Pharmaceuticals Inc | 2014-02-12 | 10 percent owner |
| MDVN | Medivation Inc | 2011-06-07 | 10 percent owner |
| JPAK | Jpak Group Co Ltd | 2007-08-09 | 10 percent owner |
Qvt Associates Gp Llc Latest Holdings Summary
Qvt Associates Gp Llc currently owns a total of 5 stocks. Among these stocks, Qvt Associates Gp Llc owns 13,326,916 shares of Medivation Inc (MDVN) as of June 7, 2011, with a value of $1.1 Billion and a weighting of 71.16%. Qvt Associates Gp Llc owns 22,860,013 shares of Urovant Sciences Ltd (UROV) as of June 19, 2019, with a value of $371 Million and a weighting of 24.34%. Qvt Associates Gp Llc also owns 8,868,753 shares of Achillion Pharmaceuticals Inc (ACHN) as of June 16, 2014, with a value of $60 Million and a weighting of 3.93%. The other 2 stocks Sio Gene Therapies Inc (SIOX) , Agenus Inc (AGEN) have a combined weighting of 0.57% among all his current holdings.
Latest Holdings of Qvt Associates Gp Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MDVN | Medivation Inc | 2011-06-07 | 13,326,916 | 81.44 | 1,085,344,039 |
| UROV | Urovant Sciences Ltd | 2019-06-19 | 22,860,013 | 16.24 | 371,246,611 |
| ACHN | Achillion Pharmaceuticals Inc | 2014-06-16 | 8,868,753 | 6.76 | 59,952,770 |
| SIOX | Sio Gene Therapies Inc | 2019-03-18 | 13,244,048 | 0.48 | 6,330,655 |
| AGEN | Agenus Inc | 2014-02-05 | 462,963 | 4.97 | 2,300,926 |
Holding Weightings of Qvt Associates Gp Llc
Qvt Associates Gp Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Qvt Associates Gp Llc has made a total of 0 transactions in Medivation Inc (MDVN) over the past 5 years. The most-recent trade in Medivation Inc is the sale of 1,472,588 shares on June 7, 2011, which brought Qvt Associates Gp Llc around $8 Million.
According to the SEC Form 4 filings, Qvt Associates Gp Llc has made a total of 8 transactions in Urovant Sciences Ltd (UROV) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Urovant Sciences Ltd is the acquisition of 18,204 shares on June 19, 2019, which cost Qvt Associates Gp Llc around $151,457.
According to the SEC Form 4 filings, Qvt Associates Gp Llc has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 1,819,551 shares on June 16, 2014, which brought Qvt Associates Gp Llc around $14 Million.
More details on Qvt Associates Gp Llc's insider transactions can be found in the Insider Trading History of Qvt Associates Gp Llc table.Insider Trading History of Qvt Associates Gp Llc
- 1
Qvt Associates Gp Llc Trading Performance
GuruFocus tracks the stock performance after each of Qvt Associates Gp Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Qvt Associates Gp Llc is 2.39%. GuruFocus also compares Qvt Associates Gp Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Qvt Associates Gp Llc within 3 months outperforms 15 times out of 23 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Qvt Associates Gp Llc's insider trading performs compared to the benchmark.
Performance of Qvt Associates Gp Llc
Average Return
57.85%
Outperforming Transactions
91%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.94 | 2.39 | 34.07 | 57.85 | 105.66 | 61.21 |
| Relative Return to S&P 500(%) | 3.96 | -3.81 | 22.48 | 49.32 | 93.38 | 47.86 |
Qvt Associates Gp Llc Ownership Network
Ownership Network List of Qvt Associates Gp Llc
Ownership Network Relation of Qvt Associates Gp Llc
Qvt Associates Gp Llc Owned Company Details
What does Arbutus Biopharma Corp do?
Who are the key executives at Arbutus Biopharma Corp?
Qvt Associates Gp Llc is the director & 10 percent owner & other: See Remarks of Arbutus Biopharma Corp. Other key executives at Arbutus Biopharma Corp include Chief Financial Officer David C Hastings , Chief Business Officer Michael J. Mcelhaugh , and Chief Scientific Officer Michael J. Sofia .
Arbutus Biopharma Corp (ABUS) Insider Trades Summary
Over the past 18 months, Qvt Associates Gp Llc made no insider transaction in Arbutus Biopharma Corp (ABUS). Other recent insider transactions involving Arbutus Biopharma Corp (ABUS) include a net sale of 10,164 shares made by Michael J. Mcelhaugh , a net sale of 9,982 shares made by Michael J. Sofia , and a net sale of 9,593 shares made by David C Hastings .
In summary, during the past 3 months, insiders sold 34,097 shares of Arbutus Biopharma Corp (ABUS) in total and bought 0 shares, with a net sale of 34,097 shares. During the past 18 months, 34,097 shares of Arbutus Biopharma Corp (ABUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 34,097 shares.
Arbutus Biopharma Corp (ABUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arbutus Biopharma Corp Insider Transactions
Qvt Associates Gp Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Qvt Associates Gp Llc. You might contact Qvt Associates Gp Llc via mailing address: 1177 Avenue Of The Americas, 9th Floor, New York Ny 10036.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
